D

    DiaMedica Therapeutics Inc (DMAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.35
    -0.04 (-0.63%)

    Market Cap: $342.43M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(24/37)
    Avg Surprise
    +1.66%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.24 - $-0.19
    4 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate Drift
    90d ago$-0.22-2.0%
    60d ago$-0.22-2.0%
    30d ago$-0.20+3.5%
    7d ago$-0.20+3.5%
    Current$-0.21
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.21
    Range$-0.28 - $-0.16
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.21---
    Sep 26EST
    		-$-0.21---
    Jun 26
    Reported Aug 10
    		$-0.19$-0.19+0.00%Beat-5.6%
    Mar 26
    Reported May 6
    		$-0.19$-0.18-5.56%Miss-5.6%
    Dec 25
    Reported Mar 30
    		$-0.17$-0.17+2.86%Beat+5.6%
    Sep 25
    Reported Nov 12
    		$-0.17$-0.16-6.25%Miss-13.3%
    Jun 25
    Reported Aug 12
    		$-0.18$-0.19+5.26%Beat-38.5%
    Mar 25
    Reported May 13
    		$-0.18$-0.18+0.00%Beat-28.6%
    Dec 24
    Reported Mar 17
    		$-0.18$-0.17-4.35%Miss-28.6%
    Sep 24
    Reported Nov 13
    		$-0.15$-0.15+0.00%Beat-25.0%
    Jun 24
    Reported Aug 7
    		$-0.13$-0.16+18.75%Beat+18.8%
    Mar 24
    Reported May 8
    		$-0.14$-0.16+12.50%Beat+30.0%
    Dec 23
    Reported Mar 19
    		$-0.14$-0.14+0.00%Beat+0.0%
    Sep 23
    Reported Nov 13
    		$-0.12$-0.13+7.69%Beat+0.0%
    Jun 23
    Reported Aug 14
    		$-0.16$-0.18+11.11%Beat-23.1%
    Mar 23
    Reported May 15
    		$-0.20$-0.16-25.00%Miss-53.8%
    Dec 22
    Reported Mar 28
    		$-0.14$-0.14+0.00%Beat-27.3%
    Sep 22
    Reported Nov 9
    		$-0.12$-0.15+20.00%Beat+33.3%
    Jun 22
    Reported Aug 10
    		$-0.13$-0.18+27.78%Beat+23.5%
    Mar 22
    Reported May 4
    		$-0.13$-0.21+38.10%Beat+31.6%
    Dec 21
    Reported Mar 14
    		$-0.11$-0.18+38.89%Beat+52.2%
    Sep 21
    Reported Nov 10
    		$-0.18$-0.23+21.74%Beat+5.3%
    Jun 21
    Reported Aug 11
    		$-0.17$-0.22+22.73%Beat+0.0%
    Mar 21
    Reported May 5
    		$-0.19$-0.22+13.64%Beat+0.0%
    Dec 20
    Reported Mar 10
    		$-0.23$-0.17-35.29%Miss-9.5%
    Sep 20
    Reported Nov 4
    		$-0.19$-0.15-26.67%Miss+5.0%
    Jun 20
    Reported Aug 11
    		$-0.17$-0.13-30.77%Miss+19.0%
    Mar 20
    Reported May 13
    		$-0.19$-0.28+32.14%Beat+29.6%
    Dec 19
    Reported Mar 23
    		$-0.21$-0.25+16.00%Beat+8.7%
    Sep 19
    Reported Nov 13
    		$-0.20$-0.21+4.76%Beat-185.7%
    Jun 19
    Reported Aug 13
    		$-0.21$-0.26+19.23%Beat+65.0%
    Mar 19
    Reported May 13
    		$-0.27$-0.20-35.00%Miss-35.0%
    Dec 18
    Reported Mar 19
    		$-0.23$-0.20-15.00%Miss-35.3%
    Sep 18
    Reported Nov 19
    		$-0.07N/A+56.25%Beat+65.0%
    Jun 18
    Reported Aug 29
    		$-0.60$-0.16-275.00%Miss-400.0%
    Mar 18
    Reported Apr 30
    		$-0.20$-0.16-25.00%Miss-1.2%
    Sep 17
    Reported Nov 27
    		$-0.17$-0.16-6.25%Miss-
    Jun 17
    Reported Aug 29
    		$-0.20$-0.14-42.86%Miss-
    Mar 17
    Reported Apr 27
    		$0.20$-0.16+225.00%Beat-
    Sep 16
    Reported Nov 29
    		$-0.20N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-8.82EV/EBITDA-0.96x
    Price/FCF-10.85xFCF Yield-9.22%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-114.60%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio6.72xQuick Ratio6.72x
    Trading Statistics
    Beta0.97Avg Volume128.58K
    52-Week High$10.4252-Week Low$5.14

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.59
    SMA 20$6.65
    SMA 50$6.87
    SMA 200$7.19
    EMA 10$6.57
    EMA 20$6.64
    EMA 50$6.67
    EMA 200$6.72

    MACD

    Line: -0.07Signal: -0.05Hist: -0.02

    ADX

    ADX: 10.7+DI: 16.7-DI: 24.2

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down100.0
    PSAR$6.78

    Bollinger Bands

    Upper Band$6.94
    Lower Band$6.37
    %B Position860%(Upper)
    Band Width-0.03

    RSI (14-Day)

    Neutral
    40.4

    Momentum Oscillators

    Stoch %K24.5
    Stoch %D35.9
    Williams %R-85.7
    ROC (10d)-4.1%
    Momentum-0.27
    CCI (20d)-183.0
    MFI (14d)33.5

    Volatility Measures

    ATR (14d)$0.33(5.1%)
    StdDev (20d)0.14
    Hist Vol34.8%(Moderate)

    Volume Flow

    VWAP$6.39
    OBV10.8M
    AD Line-3.7M
    CMF (20d)-0.146

    Volume Metrics

    Avg Vol (20d)126.4K
    Vol Ratio1.1x
    VWMA (20d)$6.66

    Pivot Points

    R3$7.04
    R2$6.89
    R1$6.64
    Pivot Point$6.49
    S1$6.24
    S2$6.09
    S3$5.84

    Advanced Oscillators

    TSI-7.94
    Ultimate Osc43.5
    KST-49.52

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$-27,999$0$0$0$13.80M$0$0$0$30.84M$0
    Cost of Revenue$0$0$13,999$0$0$0$11,000$0$0$0$8,000$0
    Gross Profit$0$0$-13,999$0$0$0$-11,000$0$0$0$-8,000$0
    Operating Expenses$10.50M$10.48M$9.21M$9.03M$8.01M$8.14M$8.42M$6.88M$5.64M$5.74M$5.85M$5.16M
    R&D$8.15M$7.99M$6.70M$6.44M$5.82M$5.66M$6.47M$4.98M$3.93M$3.68M$3.68M$3.27M
    SG&A$2.35M$2.50M$2.51M$2.60M$2.19M$2.49M$1.95M$1.90M$1.71M$2.06M$2.17M$1.89M
    Operating Income$-10,498,000$-10,482,000$-9,213,000$-9,033,000$-8,007,000$-8,144,000$-8,419,000$-6,883,000$-5,638,000$-5,741,000$-5,848,000$-5,157,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-10,132,000$-10,035,000$-8,730,000$-8,614,000$-7,693,000$-7,701,000$-7,891,000$-6,267,000$-5,112,000$-5,144,000$-5,139,000$-4,464,000
    Income Tax Expense$7,000$7,000$10,000$6,000$6,000$6,000$9,000$7,000$7,000$7,000$22,000$7,000
    Net Income$-10,139,000$-10,042,000$-8,740,000$-8,620,000$-7,699,000$-7,707,000$-7,900,000$-6,274,000$-5,119,000$-5,151,000$-5,161,000$-4,471,000
    EBITDA$-10,289,000$-10,214,000$-8,971,000$-8,845,000$-7,870,000$-7,951,000$-8,210,000$-6,622,000$-5,421,000$-5,465,000$-5,498,000$-4,880,000
    EBIT$-10,132,000$-10,035,000$-8,730,000$-8,614,000$-7,693,000$-7,701,000$-7,891,000$-6,267,000$-5,112,000$-5,144,000$-5,139,000$-4,464,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DMAC

    News

    Understanding the Setup: (DMAC) and Scalable Risk

    This article analyzes Diamedica Therapeutics Inc. (NASDAQ: DMAC), highlighting a neutral sentiment across all time horizons. It identifies a strong risk-reward setup with an exceptional 69.0:1 ratio, targeting a 20.7% gain against a 0.3% risk. The analysis provides specific entry, target, and stop-loss zones for various trading strategies, generated by AI models for different risk profiles.

    Stock Traders Daily•8/27/26•
    Neutral

    DiaMedica Therapeutics | 10-Q: Q2 2026 Earnings Report

    This document is the 10-Q filing for DiaMedica Therapeutics, specifically their Q2 2026 Earnings Report. It contains detailed financial and operational information for the company during that period.

    Moomoo•8/20/26•
    Neutral

    DiaMedica Therapeutics Inc (DMAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

    This article provides a technical analysis of DiaMedica Therapeutics Inc (DMAC), detailing its price momentum score, support and resistance levels, and indicator readings. The stock currently ranks low in its industry for price momentum and is trading between a resistance of $7.10 and support of $6.18, suggesting suitability for range-bound swing trading. The technical indicators show mixed signals, with more sell signals than buy signals across both general indicators and moving averages.

    TradingKey•8/19/26•
    Neutral

    DiaMedica Therapeutics Inc. (DMAC) stock price, news, quote and history

    This article provides a comprehensive overview of DiaMedica Therapeutics Inc. (DMAC), including its current stock price, financial statistics, historical data, and analyst insights. It highlights DMAC as a clinical-stage biopharmaceutical company focused on ischemic diseases, with its lead candidate DM199 in Phase 2/3 trials. The report also includes performance comparisons against the S&P 500 and lists similar biotechnology companies.

    Yahoo Finance UK•8/13/26•
    Neutral

    DiaMedica Therapeutics (DMAC) CEO receives 60,200 RSU award vesting over four years

    DiaMedica Therapeutics Inc.'s President & CEO, Dietrich John Pauls, was granted 60,200 restricted stock units (RSUs). These RSUs will vest in four equal annual installments, contingent on his continued service. Following this award, Pauls beneficially holds 128,791 voting common shares, including deferred share units.

    Stock Titan•8/12/26•
    Somewhat-Bullish

    Frequently Asked Questions About DMAC

    Does DMAC pay dividends?
    DiaMedica Therapeutics Inc (DMAC) does not currently pay a regular dividend.
    What is DMAC's market cap?
    DiaMedica Therapeutics Inc (DMAC) has a market capitalization of $342.43M with a current stock price of $6.35.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In